Journal issues > Issue 1, September 2024 > NEW BHS GUIDELINES ON THE MANAGEMENT OF DLBCL

NEW BHS GUIDELINES ON THE MANAGEMENT OF DLBCL

On September 24^th 2024, a webinar was held on the new Belgian Hematology Society (BHS) guidelines on the management of diffuse large B-cell lymphoma (DLBCL). Jan Brijs (UZ Leuven, Belgium & CHU Lille, France), Gilles Crochet (CHU UCL Namur, Site Godinne, Belgium) and Vibeke Vergote (UZ Leuven, Belgium) shared the latest advances in the treatment of DLBCL, both for newly-diagnosed and for relapsing or refractory (R/R) disease. These data were translated to clinical practice by the presentation of the new treatment algorithm adapted to the Belgian reimbursement criteria and the discussion of patient cases seen in daily practice.

To read the full artice you have the following options:

Click here to log in. Register for a free subscription*

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top